A detailed history of Group One Trading, L.P. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 34,699 shares of APLS stock, worth $1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
34,699
Holding current value
$1 Million
% of portfolio
0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $1.32 Million - $2.07 Million
34,699 New
34,699 $1.33 Million
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $1.01 Million - $1.76 Million
27,221 Added 12.01%
253,905 $15.2 Million
Q3 2023

Nov 09, 2023

BUY
$23.65 - $89.22 $4.92 Million - $18.5 Million
207,866 Added 1104.61%
226,684 $8.62 Million
Q2 2023

Aug 09, 2023

BUY
$76.68 - $93.31 $1.07 Million - $1.3 Million
13,908 Added 283.26%
18,818 $1.71 Million
Q1 2023

May 12, 2023

SELL
$46.59 - $66.96 $2.14 Million - $3.07 Million
-45,913 Reduced 90.34%
4,910 $323,000
Q4 2022

Feb 09, 2023

BUY
$43.24 - $61.04 $2.2 Million - $3.1 Million
50,823 New
50,823 $2.63 Million
Q2 2022

Aug 11, 2022

SELL
$35.07 - $59.21 $1.04 Million - $1.76 Million
-29,723 Reduced 53.51%
25,823 $1.17 Million
Q1 2022

May 12, 2022

BUY
$35.46 - $54.12 $692,356 - $1.06 Million
19,525 Added 54.2%
55,546 $2.82 Million
Q4 2021

Feb 11, 2022

SELL
$30.74 - $49.16 $2.14 Million - $3.43 Million
-69,731 Reduced 65.94%
36,021 $1.7 Million
Q3 2021

Nov 12, 2021

BUY
$31.4 - $69.84 $3.32 Million - $7.39 Million
105,752 New
105,752 $3.49 Million
Q4 2020

Feb 10, 2021

SELL
$30.79 - $57.2 $50,156 - $93,178
-1,629 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$25.89 - $33.65 $42,174 - $54,815
1,629 New
1,629 $49,000
Q4 2019

Feb 10, 2020

SELL
$22.1 - $30.8 $2,210 - $3,080
-100 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$24.09 - $32.18 $2,409 - $3,218
100 New
100 $2,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.17B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.